TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

6 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • DepressionAnxiety

    Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

    Testing psilocybin-assisted therapy for depression and anxiety in people with advanced cancer

    💵 May compensate

    📍 MD Anderson Cancer Center · Houston, TX · Get directions →

    To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.

    ✓ Study care freePhase 2Ages 25+Learn more →
  • Depression

    Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

    Testing ketamine infusions plus brief counseling for veterans with low back pain and depression

    💵 May compensate

    📍 VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, MI · Get directions →

    This is a pilot study to evaluate the feasibility, acceptability, and safety of ketamine infusions followed by a brief behavioral intervention in Veterans with chronic low back pain and depression.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • DepressionAnxiety

    TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

    Testing psilocybin-assisted therapy for depression and anxiety in cancer survivors

    💵 May compensate

    📍 The University of Texas M. D. Anderson Cancer Center · Houston, TX · Get directions →

    This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • DepressionAnxiety

    Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

    Testing whether pregnenolone pills affect brain function and depression in people with HIV

    💵 May compensate

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications.

    ✓ Study care freePhase 2Ages 18–85Learn more →
  • Depression

    Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial

    Testing whether a brain response to L-DOPA can track outcomes in late-life depression

    💵 May compensate

    📍 St. Paul's Hospital · Vancouver, British Columbia · Get directions →

    Background Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired.

    ✓ Study care freePhase 2Ages 60+Learn more →